Lecture 30
Cystic Fibrosis (part II) 
Vectors used for gene therapy clinical trials
Vectors
Objectives:
• Determine the safety and tolerability of repeated doses of aerosolized AAV2
vector encoding the complete human CFTR cDNA.
• Evaluation of pulmonary function, lung abnormalities, cytokines, vector shedding, serum neutralizing antibody, and expression of transgene in patients.
Method:
Cystic fibrosis patients with mild lung disease were selected for eight different cystic fibrosis centers in the United States. Subjects were give a dose of 1×10 13 recombinant adeno-associated virus containing CFTR gene nalong with appropritate control.
Observation:
No adverse effects or laboratory abnormalities was noted between the treatment groups. Vector shedding in sputum was observed in the patients. All subjects receiving CFTR gene exhibited an increase in serum AAV2-neutralizing antibodies.
Conclusions:
From this clinical trial it was concluded that the repeat doses of aerosolized AAV2 containing CFTR gene were safe and well tolerated. It resulted in encouraging improvement in pulmonary function in patients with cystic fibrosis. 
Method:
Subjects with age greater than 18 years having FEV1 more than 50% and nasal potential difference (NPD) isoproterenol response ≥-5mV were allowed to enter in this study.
The study subjects were subjected to a double-blind, dose escalation gene transfer trial. Placebo (saline) or compacted DNA was superfused or administered onto the inferior turbinate of the right or left nostril. Using the polyethylene glycol substituted 30-mer lysine peptides the plasmid DNA carrying the CFTR gene was compacted into DNA nanoparticles. These DNA nanoparticles were then administered through the nasal mucosa. The study was conducted for three dose levels (DLI, DLII, DLIII).
Some facts:
It is to be noted that the forced expiratory volume in 1 second (FEV1) > 50% and NPD ≥-5mV is the characteristic feature of classical cystic fibrosis.
DNA was administered), 4 in DLII (2.67 mg DNA was administered), and 6 in DLIII (8.0 mg DNA was administered). The primary trial assessment end points were safety and tolerability, and secondary trial assessment end point was gene transfer. Along with the primary and secondary trial assessment the routine clinical assessments and laboratory tests were performed. The subjects were serially evaluated for serum IL-6, complement, and C-reactive protein. The nasal washings were taken for cell counts, protein, IL-6, and IL-8. The pulmonary function and hearing tests were also performed.
Observation:
Following the tests conducted on the subjects
• Occurrences of no serious adverse events took place, and no events were attributed to compacted DNA.
• Association of serum or nasal washing inflammatory mediators with administered compacted DNA was not observed.
• On day 14, vector polymerase chain reaction (PCR) analysis showed a mean value in DLIII nasal scraping samples of 0.58 copy per cell.
• In the eight study subjects partial to complete NPD isoproterenol responses were observed in one of the two test subjects in DLI, three of the four test subjects in DLII, and four of the six test subjects in DLIII.
• After gene transfer the corrections persisted for as long as 6 days in almost all the subjects, in one of the subjects the correction persisted for 28 days.
From this study it was concluded that the compacted DNA nanoparticles can be safely administered to CF subjects through nasal mucosa, vector gene transfer was confirmed and partial NPD correction was observed.
Lecture 31
Duchenne Muscular Dystrophy
Introduction
One out of 3500 boys is born with the Duchenne muscular dystrophy (DMD). 
Dystrophin gene
The dystrophin gene is located on the short arm (p arm) of the X chromosome at the band 2, sub-band 1 and sub-sub-band 2 (Xp21. The dystrophin glycoprotein complex (DGC) also called costamere, acts as a bridge between the cytoskeleton, plasma membrane and the basal lamina. The dystroglycan is made of two subunits (α, β). The α-dystroglycan binds to laminin-2 (merosin) protein whereas the β-dystroglycan binds to the cysteine rich region of dystrophin. Sarcoglycans bind to the biglycans and the collagen and forms a tight complex. Syntrophins (peripheral membrane protein) bind to the C-terminal region of the dystrophin. The structure of DGC has been illustrated in the figure 31.1. 
Symptoms of DMD
The symptoms of DMD can be seen in early childhood days (before age 6) and sometimes during infancy. The characteristic symptom of DMD includes delay of motor neuron activity which independently affects sitting and standing ability. Due to delay in achieving control over the muscle movement the child affected with DMD takes longer time to start walking as compared to normal children. The mean age for walking in boys with DMD has been recorded to be about 18 months. Muscle weakness of the legs and pelvis region progresses with age and the loss of muscle mass also known as muscle wasting takes place. The enlargement of calf muscle occurs followed by the replacement of the muscle tissue by fat and connective tissue generally termed as the "pseudohypertrophic condition". Weakness in the muscle results in a characteristic way of walking called as "waddling gait". Due to the tightening of tendons around the heels, the person has to walk on tiptoes resulting in "lordosis" (development of forward curvature of the spine). The affected person finds difficulty in walking and climbing stairs. The muscles of the lower half of the body weakens earlier and more severely than the muscles of other parts of the body like the shoulder, arms, neck etc. In the later stages the affected person is unable to walk (gets confined to the wheelchair) followed by "scoliosis" (curvature of spine to the sides) and "contractures" (tightening of joints). In the last stages of the disease weakening of chest muscle and heart muscle takes place resulting in severe respiratory problem.
Death takes place due to heart failure (cardiomyopathy) or respiratory failure.
Diagnosis of DMD
DMD can be diagnosed by the symptoms as well as by measuring the amount of creatinine phosphokinase enzyme level in the blood serum. This enzyme is involved in muscle degeneration and an elevated level of this enzyme (around 20-100 times more than the normal level) is indicative of DMD. Other tests to confirm DMD includes muscle tissue biopsy, electromyography (EMG) and molecular tests.
The mdx mouse
To understand the underlying mechanism involved in the process of muscle degeneration and regeneration, the animal model being used is the mdx mouse. The dystrophic mdx mouse contains a point mutation that causes a change in the codon in the dystrophin gene resulting in changeover of glutamine amino acid to termination codon (CAA, CAG encodes for glutamine which may be changed by replacement of any of the three letters with T. In case the C in CAA and CAG is replaced by T then it becomes TAA and TAG, which are stop codons and result in premature stop of dystrophin synthesis and formation of non functional dystrophin in the muscle). All experiments related to DMD use the mdx mouse as the animal model. From the beginning, different stages of skeletal muscle degeneration and subsequent regeneration can be observed in the mdx mouse. As the mdx mouse grows old generally the diaphragm muscle weakens followed by development of fibrosis in the muscle.
Treatments for DMD
Since the size of dystrophin gene is large, it is susceptible to random mutations. It has been observed that almost two third DMD cases are due to deletion mutation within dystrophin gene whereas one third DMD cases are due to nonsense point mutation which affects the reading frame of the transcript. As a result of nonsense point mutation truncated and non-functional dystrophin protein is formed.
Till date no cure for DMD has been found. Thus, the current therapies aim at increasing the quality of life of the patient by controlling the symptoms.
Pharmacological strategy involves:
a) The use of a cocktail of drug like prednisone and deflazacort or prednisone Since the size of the dystrophin cDNA is very large (14Kbp) and in addition the size of the vector (adenovirus) is also large thus it cannot easily enter the mature myofibre.
The myofibre also lacks adenovirus receptors. Adeno-associated virus (AAV) has a smaller size and can be used instead of adenovirus. Limitation of using AAV is that it cannot carry the dystrophin cDNA (since size of dystrophin cDNA is very large).
Thus, the truncated cDNA has to be used. It is known that the dystrophin protein consists of N-terminus, C-terminus, cysteine rich region and central rod region.
Cysteine rich region, N and C terminus are essential for maintaining the integrity of the DGC thus; the truncated cDNA may be shortened at the central rod shaped domain while retaining the whole N-terminus, C-terminus, cysteine rich region and some portion of the central rod region. The reduced cDNA produced as a result of deleted portions of central rod region is known as the dystrophin mini-gene. The dystrophin mini-gene can be easily inserted into the AAV which has good transfection efficiency as a result the mini dystrophin gene can be successfully targeted to the muscle cells. To overcome the lack of receptors for adenovirus on the myofibre, monoclonal antibodies with specific binding at one end for the adenovirus and another end to various receptors (like integrin) on myofibre cells can be used.
Complete gene as DNA:
The whole dystrophin cDNA can be inserted into the plasmid and injected into the blood stream. The limitation of this method is low transfection efficiency and high dose requirement for successful transfection.
Electroporation, ultrasound as well as non-viral vectors may be used for delivery of the target gene to the target tissue.
Chimeraplasty:
Chimeraplasty utilizes the endogenous repair mechanism, which may be used for repairing the defective dystrophin gene.
Supressing premature termination:
Gentamycin, an amino glycoside, has been reported to suppress the premature termination (due to stop codon generated as a result of mutation) and enable the synthesis of 20% functional dystrophin protein in mdx mouse. Its efficacy in human subjects has not been ascertained till date.
Exon skipping:
Exon skipping is another technique which may be employed to elevate the effects of DMD by making it milder like BMD. In DMD dystrophin is absent as ribosome encounters premature stop codon thus by skipping the mutated exon the rest of the shorter functional truncated dystrophin can be synthesized. The purpose of exon skipping is to induce the splicing mechanism and remove the introns from the pre mRNA and exons before and after the point mutation or deletion and thus enable read through the rest of the exon as in normal condition.
In order to perform exon skipping antisense oligoribonucleotides (AONs) have to be This study confirms that rationally designed AAV2.5 vector was safe and well tolerated and forms the basis of designing AAV vectors that best suit the clinical objective (e.g., limb infusion gene delivery).
Challenges faced by gene therapy
• Immune rejection of the foreign protein, plasmid and DNA by the target cells.
• Localization of the desired gene product.
• Insertional mutagenesis risk due to use of viral vectors since the viral vector genome may integrate with the host genome.
Lecture 32
Bleeding Disorders (part I)
Introduction
Blood In this lecture initially, we shall understand the importance and mechanism of blood clotting followed by disorders related to blood and the available remedies.
Process of blood clotting:
A simplified schematic below depicts the process of blood clotting. During any injury if a blood vessel ruptures then the blood gets exposed to the subendothelial tissue where the plasma enzyme activation cascade begins to function. The endothelium has a unique feature of allowing proper fluidity at normal condition but when it encounters injury, it starts the coagulation process (mediated by various factors and secretions of the endothelial cell) in order to contain the injury and prevent any further loss of blood.
Normally, endothelial cells are not involved in the synthesis of tissue factors but when they encounter cytokines or interact with monocytes they begin to synthesize the tissue factor. The tissue factors are glycosylated intrinsic membrane proteins, which come in contact with blood only when there is any injury. They are located on the adventitious side of the endothelial cells hence do not come in contact with blood under normal condition. There are two classical pathways of blood clotting extrinsic and intrinsic. Since, the tissue factor is an extrinsic protein thus, the clotting initiated by tissue factor falls under the extrinsic pathway. All the blood clotting factors are present in the plasma hence coagulation due to the internal components of plasma falls under the intrinsic pathway. The intrinsic pathway name is derived from the fact that all the clotting factors required for blood clotting is present "within" the plasma. Let us understand the steps involved in this pathway.
• The first plasma protein involved in the intrinsic pathway is called Hageman factor or factor XII. Factor XII is initially in inactive state but on activation becomes factor XIIa. Factor XII converts to factor XIIa only when it comes in contact with rough surface like the collagen fibres underlying damaged endothelium.
• This process of activation is called contact activation and is a complex process requiring the participation of several other plasma proteins.
• Factor XIIa then catalyzes the activation of factor XI to factor XIa which then causes activation of factor IX to factor IXa.
• Factor IXa then activates factor X to factor Xa which is the enzyme responsible for the conversion of prothrombin to thrombin.
• Another plasma protein factor VIIIa serves as a cofactor (not an enzyme) in the factor IXa mediated activation of factor X.
The importance of factor VIII in clotting can be understood by the fact that the disease hemophilia which causes excessive bleeding occurs due to the absence of this factor. In few cases, hemophilia has been reported due to an abrupt loss or absence of factor IX. Now, let us understand the steps involved in the extrinsic pathway for initiating the clotting cascade.
• As explained in the introduction, this pathway involves an intrinsic membrane protein called the tissue factor. It is not a plasma protein and is located on the adventitious surface or the outer surface of the plasma membrane of various tissue cells, including fibroblasts and other cells in the walls of blood vessels below the endothelium.
• The blood when exposed to the subendothelial cells during vessel damage (causing disruption in the endothelial lining) comes in contact with the tissue factor on these cells which bind to factor VII (a plasma protein). Factor VII is activated to factor VIIa.
• The complex formation between the tissue factor and the factor VIIa takes place on the plasma membrane of the tissue cell. Once the complex is formed it begins the catalytic activation of the factor X.
• Tissue factor and factor VIIa complex also performs the catalytic activation of factor IX, resulting in the catalytic activation of larger quantity of factor X by entering into the intrinsic pathway. As a result amplification in the production of Xa takes place.
In short, by the mechanism studied till now we can assume that clotting begins either by the activation of factor XII to XIIa or by the formation of the tissue factor and factor VIIa complex.
Common pathway:
The paths, the intrinsic as well as the extrinsic, can be seen to merge at factor Xa as shown in the schematic representation below. This activated Xa begins the catalysis and converts prothrombin to thrombin.
Once thrombin is formed it is believed to be involved in three main functions. 
Hemophilia B
is also a recessive X-linked genetic disorder the cause of which is the lack of a functional factor IX (Christmas factor). This disease is also known as Christmas disease. Almost 20% of hemophilia cases. Are of hemophilia B type. This disorder presents itself in 1 out of 34,000 male live births. The cause behind hemophilia B is the mutated factor IX gene.
Hemophilia C unlike the hemophilia A and B is not a recessive X-linked
disorder but it is an autosomal genetic disorder the cause of which is the lack of functional factor XI. Haemophilia C is incompletely recessive because even in heterozygous individuals high amount of bleeding has been reported. The cause behind hemophilia C is the mutated factor XI present on chromosome number 4. Page 34 of 46
The schematic diagrams below (figure 33.1) may be referred to understand the functionalities of the factor VIII, IX and XI. The implications associated with the mutation in these factors and their impact on the clotting mechanism can thus be understood. This disease causes death of individuals who meet with accidents as well as individuals where internal haemorrhage takes place. This disease needs to be seriously addressed.
Figure 33.1 Difference between a normal and hemophilic condition:
When injury occurs and the blood vessel starts leaking out blood then the attachment of platelets at the site of injury enables the vasoconstriction i.e. narrowing of the blood vessel to prevent blood loss. The activation of clotting factors is initiated.
Under normal circumstances the blood clotting involves the strong platelet plug formation due to the factor VIII. It stabilizes the fibrin clot and seals the injured tissue thus, stops bleeding. Fibrinolysis is the process used to clear the clot after wound recovery. In haemophilic condition the factor VIII is absent that causes the formation of weak platelet plug. Thus, the wound is not properly sealed hence continuous loss of blood due to leakage through loose fibrin clot takes place. Excessive bleeding may cause death of the individual.
Various vectors used for gene therapy of hemophilia
Adeno-associated virus (AAV) is the most used virus vector for the clinical trials conducted for hemophilia. This virus is of small size, well known and characterized for its effective gene therapy application. Retroviruses have also been used. Non-viral vectors are also being explored as an alternative to the AAV.
The schematic representation below shows the simplified method of gene therapy strategy being used for the treatment of hemophilia. Here the gene encoding for Factor VIII is inserted inside the viral vector and the human cell is infected with this virus. The gene enters the cell, reaches the nucleus and integrates at specific site.
The gene is transcribed inside the cell and the functional factor VIII protein is synthesized which effectively elevates or overcomes the limitations of coagulation of the blood. The mice were traumatized by injuring their feet using a mouse restrainer. In case of knock-out mice swollen extremities and hematoma were very prominent whereas, these were found to be reduced in the wild type and heterozygous mice.
Using Activated Partial Thromboplastin Time (APTT) assay the factor IX coagulant activity in all three mice wild type (+/+), heterozygous (+/−) and knock-out (−/−) was quantitatively estimated and was found to be 92.1 ± 19.1% for the wild type (+/+), 52.9 ± 10.4% for the heterozygous (+/−) and 5.4 ± 2.9% for the knock-out (−/−) mice.
This study was successful in terms of creating Factor IX knock-out mice.
Development of WAG-F8 (m1Ycb) rats harboring a factor

VIII gene mutation
In 2010 Booth et al., developed a rat model for factor VIII in order to study the hemophilia A condition. The main objective of this study was
• The determination of precisely specific factors in the coagulation mechanism in the WAG/RijYcb rats..
• Finding out the genetic defect associated or responsible for the hereditary clotting defect (inherited coagulopathy) in the WAG/RijYcb rats.
The factors responsible for clotting were evaluated and properly assessed for their activity. The animals harboring the mutation were affected and on evaluation of individual clotting factor activities it was found that the affected animals were deficient in a specific factor VIII (FVIII). The FVIII gene is located on the autosome (chromosome number 18) in rats whereas in human and mice it is located on the X chromosome. When the factor VIII cDNA was sequenced it was found that a point mutation, resulting in a substitution of Leucine at 176 th position by Proline (L176P), in the A1 domain of the factor VIII protein had occurred. This mutation is responsible for the disruption of the tertiary structure of the FVIII protein molecule.
When the affected animals were administered with the human plasma or human recombinant FVIII it rectified the coagulation defects.
From this study it can be concluded that this model is unique because the size of the rat is larger as compared to mice and this coagulation defect is present in both sexes. This model can be effectively used to study and develop new therapies for both hereditary as well as the acquired factor VIII deficiency.
Gene therapy studies on hemophilia
In 
Results
Expression of factor IX increased by 2 to 11% of the normal levels was observed in all study subjects. Out of the 6 study subjects 4 discontinued factor IX treatment and remained free of spontaneous hemorrhage whereas in the other two the duration between prophylactic injections was increased. The study subject out of the two who were administered the high dose of scAAV2/8-LP1-hFIXco vector, one was observed to develop a transient, asymptomatic elevation of serum aminotransferase levels. This elevation was due to the formation of AAV8-capsid-specific T cells in the peripheral blood. The other study subject was observed to develop a small increment in the liver-enzyme levels the cause of this increment was not deduced.
Conclusions
The administration of scAAV2/8-LP1-hFIXco vector via Peripheral-vein infusion caused an enhanced factor IX transgene expression capable of improving the coagulation in study subjects with the bleeding phenotypic trait along with few side effects.
Lecture 34 Tyrosinemia
Introduction
Tyrosinemia is a genetic disorder which is characterized by the accumulation of the amino acid tyrosine in the blood. Tyrosine is a building block of most proteins.
The level of this amino acid in the blood is regulated by tyrosine catabolic pathway, a multistep process that involves a number of enzymes. The cause of Tyrosinemia is the deficiency or shortage of one of the enzymes involved in the tyrosine catabolic pathway.
In untreated condition the tyrosine and its byproducts accumulate in tissues and various organs. Serious medical problems like liver failure, hepatocellular carcinoma, kidney dysfunction, skeletal changes and neurological manifestations are associated with the accumulation of tyrosine and its byproducts in the blood hence, it is important to address this problem and find a suitable treatment for this disease.
Tyrosine catabolic pathway
• In the presence of phenylalanine hydrolase phenylalanine is converted to tyrosine.
• Tyrosine aminotransferase causes the conversion of tyrosine to 4-hydroxyphenylpyruvate (4HPP).
• 4-HPP is converted to homogentisate (2,5-dihydroxyphenylacetate) in the presence of the enzyme 4-HPP dioxygenase (HPPD) which is an Fe(II) dependent non-heme oxygenase. NTBC (2-[2-nitro-4-(trifluoromethyl) benzoyl] cyclohexane-1,3-dione) or nitisinone is a triketone which inhibits the enzyme 4-HPP dioxygenase (4-HPD) reversibly thus preventing the formation of maleylacetoacetic acid and fumarylacetoacetic acid. As a result, it prevents the formation and accumulation of toxic succinylacetone and succinyl acetoacetate. NTBC is successfully being used to treat type I tyrosinemia patients.
• Homogentisate is oxidized by the enzyme homogentisate oxidase to maleylacetoacetate.
• Maleylacetoacetate is converted to its isomeric form fumarylacetoacetate by the enzyme maleylacetoacetate isomerase.
• Fumarylacetoacetate is converted to fumarate and acetoacetate in the presence of fumarylacetoacetate hydrolase (FAH).
Figure 34.1 Tyrosine catabolic pathway:
The schematic representation below shows tyrosine catabolic pathway and its related diseases. children. Since they lack the enzyme FAH, so cannot convert fumarylacetoacetic acid into fumaric acid. Instead, fumarylacetoacetic acid is converted to succinylacetoacetate and then to succinylacetone which is toxic for liver, kidneys and brain.
Successful treatment is available nowadays with medication and controlled diet. The symptom of this disorder usually appears in the first few months of life and includes:
• Failure to thrive or failure to grow and gain weight at the expected normal rate.
• Jaundice, characterized by the yellowing of the skin and whites of the eyes.
• Cabbage-like odor
• Vomiting.
• Diarrhea.
• An increased tendency to bleed (particularly nosebleeds).
Type I tyrosinemia can lead to permanent liver and kidney failure. The nervous system is affected and increased chances of liver cancer persist in this disorder.
Type II Tyrosinemia:
It is caused by a deficiency of the enzyme tyrosine aminotransferase (TAT) due to defect in the TAT gene. The organs affected by Type II tyrosinemia include eyes and skin. Impaired mental development has also been observed in patients with this disorder. The symptom of this disorder usually appears in the early childhood and includes:
• Excessive tear formation.
• Photophobia or abnormal sensitivity to light.
• Redness and pain in the eyes.
• Development of painful skin lesions on the palms and soles.
• Mental disability (about 50 percent of individuals affected with type II tyrosinemia have some degree of intellectual disability).
34.3.3 Type III Tyrosinemia: It is a rare disorder caused by a deficiency of the enzyme 4-hydroxyphenylpyruvate dioxygenase (HPD) due to defect in the HPD gene. Characteristic features of this disorder usually include:
• Intellectual disability
• Intermittent ataxia or seizures, and periodic loss of balance and coordination.
Treatments for Tyrosinemia
There are three strategies other than the gene therapy being used to treat tyrosinemia.
• Controlled diet (the use of a diet low in tyrosine and phenylalanine to minimize the amount of tyrosine that needs to be metabolized): A diet with very low phenylalanine and tyrosine should be started immediately upon diagnosis of tyrosinemia. The diet should support an appropriate rate of growth, normal intellectual development, provide adequate nourishment and prevent neurological crisis, liver and kidney dysfunction, and formation of tyrosine crystals in the eyes.
• Medication: Nitisinone or NTBC (brand name Orfadin ® ) is a medication that has shown good results.
• Liver transplantation: In case of acute liver damage there is no option but liver transplantation.
Determination of the efficacy of the treatment is monitored by frequently measuring the concentration of phenylalanine, tyrosine, succinylacetone, all amino acids, albumin, prealbumin, and haemoglobin in blood. Liver function studies should also be conducted.
genomic loci with lower immunogenicity. It is capable of targeted stable expression through integration. It is low mutagenic and a vector of choice for gene repair because its single stranded nature facilitates correction by homologous recombination.
However, many drawbacks to gene repair therapy remain. Most notable drawback of this system is the low frequency of correction in vivo and thus is of no therapeutic value for any disease.
Method: A mouse model of hereditary tyrosinemia type I with a point mutation was used to test whether targeted AAV integration by homologous recombination could achieve high level stable gene repair in vivo or not.
To conduct this study both the neonatal and adult mice were treated with AAV serotypes 2 and 8 carrying a wild-type genomic sequence for repairing the mutated FAH gene.
Observation:
• Gene repair was successful with both serotypes having AAV-8 more efficient than AAV-2.
• Frequencies of correction were up to 10 -3 .
• It was observed that the repaired hepatocytes had a selective growth advantage and were able to proliferate efficiently. The repopulation of the mutant livers with corrected gene carrying hepatocytes occurred and the underlying metabolic disease was cured.
